Early results of a phase I evaluation of TAK-228 (TORC 1/2 inhibitor) in combination with TAK-117 (PI3K alpha inhibitor) and paclitaxel in advanced gynecologic malignancies and metastatic breast cancerCasey Williams, David Starks, Kirstin Williams et al.|Gynecologic Oncology|2019Cited by 0
List of ContributorsMargaret Adams, John Flaskos, Daiana Silva Ávila et al.|Elsevier eBooks|2011Cited by 0